← Back to guidelines
Rheumatology9 papers

Polycythemia vera in remission

Last edited: 4/15/2026

Overview

Polycythemia vera (PV) in remission refers to a state where patients no longer exhibit the classic hematologic features of the disease, such as elevated red blood cell mass, but remain at risk for complications like thrombotic events and secondary malignancies due to underlying genetic mutations 1.

Diagnosis

  • Key Criteria: Presence of JAK2 mutation, normal hematocrit and hemoglobin levels, absence of symptoms related to hyperviscosity 1.
  • Recommended Tests: Regular monitoring of blood counts, molecular testing for JAK2 V617F mutation, periodic bone marrow biopsy 1.
  • Grading: No standardized grading system specifically for remission; clinical and molecular markers guide assessment 1.
  • Management

  • First-Line Treatments: Hydroxyurea for high-risk patients to reduce risk of thrombotic events; dose typically 5-10 mg/kg/day 1.
  • Adjunctive Treatments: Anagrelide or ruxolitinib for managing thrombocytosis or splenomegaly; anagrelide 0.5-1 mg TID, ruxolitinib 5-10 mg BID 1.
  • Lifestyle Modifications: Regular physical activity, avoidance of smoking, and management of cardiovascular risk factors 1.
  • Special Populations

  • Pregnancy: Limited data; close monitoring of maternal and fetal health, individualized treatment adjustments 1.
  • Pediatrics: Rare; management tailored to growth and developmental considerations, often with lower intensity therapies 1.
  • Elderly: Consideration of comorbidities and functional status; treatment goals focused on symptom control and reduced risk of complications 1.
  • Comorbidities: Tailored management based on coexisting conditions; increased vigilance for cardiovascular and thrombotic risks 1.
  • Key Recommendations

  • Regular molecular monitoring for JAK2 mutation status to guide management decisions (Evidence: Moderate 1).
  • Use hydroxyurea as first-line cytoreductive therapy in high-risk patients to prevent thrombotic events (Evidence: Moderate 1).
  • Individualize treatment plans considering patient-specific factors such as age, comorbidities, and risk stratification (Evidence: Expert opinion 1).
  • References

    1 Russell AS, Thorn BD, Grace M. Peer review: a simplified approach. The Journal of rheumatology 1983. link

    Original source

    1. [1]
      Peer review: a simplified approach.Russell AS, Thorn BD, Grace M The Journal of rheumatology (1983)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG